In a second study population we used NGS to evaluate BRAFV600 mutations in pretreatment melanoma specimens from 76 patients with metastatic melanoma who subsequently received BRAF inhibitors, and examined correlations between BRAFV600 allele frequencies, PFS, overall survival (OS), and objective response. The gene discussed is BRAF; the disease is melanoma.